SCG-142

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameSCG-142
Drug Alias NameHuman papillomavirus - TCR T-cell therapy (SCG Cell Therapy)SCG-142SCG142
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsPenile NeoplasmsVulvar NeoplasmsVaginal Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSCG Cell Therapy Pte Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSCG Science (Shanghai) Co LtdSCG (Shanghai) Celltherapy Co LtdThe Affiliated Hospital Of Qingdao University +[4] 
Inactive CompaniesN/A
Active IndicationsPenile NeoplasmsVulvar NeoplasmsVaginal Neoplasms +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A